上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白,专注于信号通路和疾病研究领域。
HA-100 纯度: 99.77%
HA-100 是一种有效的蛋白激酶抑制剂,抑制 PKG,PKA,PKC 和 MLC 激酶的 IC50 值分别为 4 μM、8 μM、12 μM 和 240 μM。HA-100 也用作 ROCK 抑制剂。
HA-100 Chemical Structure
CAS No. : 84468-24-6
规格 | 价格 | 是否有货 | 数量 |
---|---|---|---|
Free Sample (0.1-0.5 mg) | Apply now | ||
10 mM * 1 mL in DMSO | ¥847 | In-stock | |
5 mg | ¥770 | In-stock | |
10 mg | ¥1300 | In-stock | |
25 mg | ¥2800 | In-stock | |
50 mg | ¥5000 | In-stock | |
100 mg | ¥9000 | In-stock | |
200 mg | 询价 | ||
500 mg | 询价 |
* Please select Quantity before adding items.
HA-100 相关产品
•相关化合物库:
- Bioactive Compound Library Plus
- Cell Cycle/DNA Damage Compound Library
- Epigenetics Compound Library
- Kinase Inhibitor Library
- Protein Tyrosine Kinase Compound Library
- Stem Cell Signaling Compound Library
- TGF-beta/Smad Compound Library
- Anti-Cancer Compound Library
- Anti-Aging Compound Library
- Reprogramming Compound Library
- Oxygen Sensing Compound Library
- Cytoskeleton Compound Library
生物活性 |
HA-100 is a potent protein kinase inhibitor, with IC50s of 4 μM, 8 μM, 12 μM and 240 μM for cGMP-dependent protein kinase (PKG), cAMP-dependent protein kinase (PKA), protein kinase C (PKC) and MLC-kinase, respectively. HA-100 also used as a ROCK inhibitor[1][2]. |
||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
IC50 & Target[1] |
|
||||||||||||||||
体外研究 (In Vitro) |
HA-100 inhibits MLC-kinase and PKC competitively with respect to ATP, with Kis of 61 and 6.5 μM, respectively[1]. 上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only. |
||||||||||||||||
分子量 |
277.34 |
||||||||||||||||
Formula |
C13H15N3O2S |
||||||||||||||||
CAS 号 |
84468-24-6 |
||||||||||||||||
运输条件 |
Room temperature in continental US; may vary elsewhere. |
||||||||||||||||
储存方式 |
|
||||||||||||||||
溶解性数据 |
In Vitro:
DMSO : 150 mg/mL (540.85 mM; Need ultrasonic and warming) 配制储备液
*
请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 In Vivo:
请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用; 以下溶剂前显示的百
|
||||||||||||||||
参考文献 |
|
所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务